Skip to main content

Generex Biotechnology Value Stock - Dividend - Research Selection

Generex Biotechnology

ISIN: US3714851033, WKN: 922012

Market price date: 27.05.2021
Market price: 0,28 USD




Generex Biotechnology Fundamental data and company key figures of the share

Annual reports in USD
Key figures 21-11-2020
Cash flow
Net operating cash flow -6.121.260
Capital Expenditures -4.616
Free cash flow -6.125.876
Balance sheet
Total Equity -21.456.000
Liabilities & Shareholders equity 45.382.900
Income statement
Net income -33.335.000
Eps (diluted) -0,460
Diluted shares outstanding 74.417.600
Net sales/revenue 2.661.400

Fundamental ratios calculated on: 27-05-2021

Ratios
Key figures 27-05-2021
Cash flow
P/C -3,65
   
P/FC -3,40
Balance sheet
ROI-73,45
ROE-47,28
Income statement
P/E-0,61
Div. Yield0,00%
P/B-1,04
P/S7,83


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolGNBT
Market Capitalization22.325.280,00 USD
Country
IndicesNO INDEX
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2020-02-25,7.000000/5.000000; 2020-01-13,7.000000/5.000000; 2020-01-06,140.000000/100.000000; 2019-12-02,2.000000/1.000000; 2019-10-31,2.000000/1.000000; 2019-10-30,2.000000/1.000000; 2019-07-23,2.000000/1.000000; 2018-12-04,21.0000/1.0000; 2018-12-03,1.0000/21.0000; 2017-03-14,1.0000/1000.0000
Internetwww.generex.com


Description of the company

Generex Biotechnology Corporation is engaged in pharmaceutical and biotechnological research and development of drug delivery systems and technologies, and other activities. The Company offers a platform technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. It develops drug delivery systems and technologies for metabolic and immunological diseases. The Company is conducting pre-clinical and human clinical trials using its technology platforms in the areas of diabetes, pain management and cancers. Its buccal insulin product, Generex Oral-lyn, provides a needle-free means of delivering insulin for the patients suffering from type I diabetes and type II diabetes. Its buccal delivery technology involves the preparation of formulations in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.generex.com